Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
RNA Avidity Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: RNA
Price (delayed)
$30.98
Market cap
$3.73B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.01
Enterprise value
$3.48B
Avidity Biosciences, Inc. is driven to change lives with a new class of therapies called Antibody Oligonucleotide Conjugates (AOCs) that are designed to overcome current limitations of oligonucleotide therapies in
Highlights
Avidity Biosciences's debt has decreased by 35% YoY and by 12% from the previous quarter
RNA's quick ratio is up by 33% YoY and by 6% from the previous quarter
The equity has soared by 60% YoY but it fell by 7% QoQ
RNA's net income has shrunk by 61% YoY and by 15% QoQ
The gross profit fell by 18% QoQ and by 18% YoY
Key stats
What are the main financial stats of RNA
Market
Valuations
Earnings
Shares outstanding
120.54M
Market cap
$3.73B
Enterprise value
$3.48B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.8
Price to sales (P/S)
448.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
390.19
Revenue
$8.93M
Gross profit
$8.93M
Operating income
-$433.27M
Net income
-$369.22M
EBIT
-$369.22M
EBITDA
-$363.01M
Free cash flow
-$365.22M
Per share
Balance sheet
Liquidity
EPS
-$3.01
EPS diluted
-$3.01
Free cash flow per share
-$2.83
Book value per share
$11.05
Revenue per share
$0.07
TBVPS
$11.29
Total assets
$1.46B
Total liabilities
$130.35M
Debt
$5.97M
Equity
$1.33B
Working capital
$1.35B
Debt to equity
0
Current ratio
16.91
Quick ratio
16.29
Net debt/EBITDA
0.69
Margins
Efficiency
Dividend
EBITDA margin
-4,066.4%
Gross margin
100%
Net margin
-4,136%
Operating margin
-4,853.4%
Return on assets
-24.6%
Return on equity
-27%
Return on invested capital
-34.7%
Return on capital employed
-26.9%
Return on sales
-4,136%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RNA stock price
How has the Avidity Biosciences stock price performed over time
Intraday
-2.27%
1 week
1.31%
1 month
-5.11%
1 year
14.49%
YTD
6.53%
QTD
4.95%
Financial performance
How have Avidity Biosciences's revenue and profit performed over time
Revenue
$8.93M
Gross profit
$8.93M
Operating income
-$433.27M
Net income
-$369.22M
Gross margin
100%
Net margin
-4,136%
RNA's operating margin has dropped by 107% year-on-year and by 40% since the previous quarter
Avidity Biosciences's net margin has plunged by 97% YoY and by 40% from the previous quarter
The operating income has plunged by 70% YoY and by 14% from the previous quarter
RNA's net income has shrunk by 61% YoY and by 15% QoQ
Price vs fundamentals
How does RNA's price correlate with its fundamentals
Growth
What is Avidity Biosciences's growth rate over time
Valuation
What is Avidity Biosciences stock price valuation
P/E
N/A
P/B
2.8
P/S
448.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
390.19
RNA's EPS is down by 4.2% from the previous quarter
The equity has soared by 60% YoY but it fell by 7% QoQ
The P/B is 12% above the 5-year quarterly average of 2.5 but 3.4% below the last 4 quarters average of 2.9
RNA's P/S is 167% above its 5-year quarterly average of 167.9 and 6% above its last 4 quarters average of 424.3
RNA's revenue is down by 18% since the previous quarter and by 18% year-on-year
Efficiency
How efficient is Avidity Biosciences business performance
RNA's ROS has plunged by 97% YoY and by 40% from the previous quarter
RNA's return on invested capital is up by 37% year-on-year and by 4.7% since the previous quarter
The ROE has grown by 29% YoY but it has contracted by 4.2% from the previous quarter
RNA's ROA is up by 26% YoY but it is down by 5% from the previous quarter
Dividends
What is RNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RNA.
Financial health
How did Avidity Biosciences financials performed over time
RNA's total assets has soared by 53% YoY but it is down by 7% QoQ
RNA's current ratio is up by 36% year-on-year and by 8% since the previous quarter
Avidity Biosciences's debt is 100% less than its equity
Avidity Biosciences's debt to equity has plunged by 100% YoY
The equity has soared by 60% YoY but it fell by 7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.